A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Serlopitant (Primary)
- Indications Epidermolysis bullosa; Pruritus
- Focus Therapeutic Use
- 06 Nov 2017 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
- 06 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2018.
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.